EcoDrugPlus

Adrenoceptor Alpha 2c

Ensembl ID : ENSAPOG00000009409
Gene Symbol: ADRA2C
1 Cross references
162 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSAPOG00000023084
Gene Symbol: ADRB1
1 Cross references
163 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSAPOG00000000080
Gene Symbol: ADRB2
3 Cross references
168 Possible Orthologues:

Aldose Reductase-Like

Ensembl ID : ENSAPOG00000012036
Gene Symbol: LOC110972333
3 Cross references
350 Possible Orthologues:

Aldose Reductase-Like

Ensembl ID : ENSAPOG00000011989
Gene Symbol: LOC110972354
3 Cross references
348 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSAPOG00000009813
Gene Symbol: GAA
3 Cross references
233 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSAPOG00000011622
Gene Symbol: LOC110957975
3 Cross references
202 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSAPOG00000009327
Gene Symbol: LOC110969423
3 Cross references
192 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSAPOG00000010578
Gene Symbol: LOC110961012
3 Cross references
156 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSAPOG00000022482
Gene Symbol: LOC110952505
3 Cross references
175 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSAPOG00000006129
Gene Symbol: AOC1
3 Cross references
233 Possible Orthologues:

Amyloid Beta A4 Protein-Like

Ensembl ID : ENSAPOG00000002239
Gene Symbol: LOC110952342
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).